Cd68-flox Mouse
一般名
Cd68-flox
製品ID
S-CKO-01636
背景情報
C57BL/6NCya
系統ID
CKOCMP-12514-Cd68-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Cd68-flox Mouse(カタログ番号S-CKO-01636)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Cd68-flox
系統ID
CKOCMP-12514-Cd68-B6N-VA
遺伝子名
製品ID
S-CKO-01636
遺伝子別名
Lamp4, gp110, Scard1
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conditional knockout
染色体
Chr 11
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000018918
NCBIトランスクリプトID
NM_001291058
ターゲット領域
Exon 1~6
有効領域の大きさ
~1.9 kb
遺伝子研究の概要
Cd68, also known as CD68 molecule, plays a critical role in promoting phagocytosis. Macrophages and other cells can express the CD68 antigen [5]. It is involved in the regulation of immune responses and has been associated with inflammation-related processes [5,6]. Genetic models, such as gene knockout (KO) or conditional knockout (CKO) mouse models, could potentially be valuable in further elucidating its functions in vivo.
In various cancers, CD68 shows significant associations. In gastric cancer, higher infiltration of SPI1+CD68+ tumor-associated macrophages (TAMs) is related to poor overall survival, and SPI1 in these macrophages promotes M2-type macrophage polarization and angiogenesis, suggesting it as a biomarker for prognosis and a target for combined anti-angiogenic and immunotherapy [1]. In Hodgkin's lymphoma, increased infiltration of CD68+ macrophages correlates with poor prognosis, as they support the survival of Reed Sternberg Cells [2]. In glioma, TIM-3/CD68 double-high expression indicates poor survival and may be a new marker, and exploring the combination of TIM-3 inhibitors and p38 MAPK inhibitor could be a treatment direction [3]. In pan-cancer analysis, CD68 levels vary in different cancer types, with high levels correlating with adverse prognosis in some cancers like glioblastoma and favorable prognosis in kidney chromophobe, and inhibiting CD68-dependent signaling could be a therapeutic strategy [4]. In non-small cell lung cancer (NSCLC), high infiltration of CD68+SHP2+ TAMs predicts poor overall survival, and targeting SHP2 may inhibit M2-phenotype polarization [7]. In hepatocellular carcinoma, a meta-analysis showed that CD68+ TAMs are significantly associated with unfavorable overall survival and disease-free survival, suggesting it as a prognostic biomarker [8]. In intracranial aneurysms, there may be an involvement of CD68 in aneurysm development but not rupture, and its expression in the aneurysmal wall is associated with aneurysm size [5,6].
In conclusion, Cd68 is involved in immune-related functions, especially in the context of tumor-associated macrophages across multiple cancer types, where it can influence prognosis and potentially serve as a biomarker or therapeutic target. In intracranial aneurysms, it may be related to the development rather than rupture. Studies using KO or CKO mouse models could further clarify its roles in these disease conditions.
References:
1. Deng, Guofei, Wang, Pengliang, Su, Rishun, Zhang, Changhua, Yin, Songcheng. 2024. SPI1+CD68+ macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies. In Journal for immunotherapy of cancer, 12, . doi:10.1136/jitc-2024-009983. https://pubmed.ncbi.nlm.nih.gov/39455096/
2. Tomarchio, Valeria, Rigacci, Luigi. 2023. Role of CD68 in the tumor immune microenvironment in Hodgkin's lymphoma. In Expert review of clinical immunology, 20, 811-819. doi:10.1080/1744666X.2023.2294943. https://pubmed.ncbi.nlm.nih.gov/38087440/
3. Hu, Wanming, Li, Depei, Yang, Yuanzhong, Zeng, Jing, Sai, Ke. 2024. TIM-3/CD68 double-high expression in Glioma: Prognostic characteristics and potential therapeutic approaches. In International immunopharmacology, 139, 112665. doi:10.1016/j.intimp.2024.112665. https://pubmed.ncbi.nlm.nih.gov/39002523/
4. Zhang, Jingwei, Li, Shuwang, Liu, Fangkun, Yang, Kui. 2022. Role of CD68 in tumor immunity and prognosis prediction in pan-cancer. In Scientific reports, 12, 7844. doi:10.1038/s41598-022-11503-2. https://pubmed.ncbi.nlm.nih.gov/35550532/
5. Rahmanian, Abdolkarim, Salehi, Ahmad, Kamali-Sarvestani, Eskandar, Jamali, Mohammad, Ghahramani, Sulmaz. 2023. CD68 Antigen and Cerebral Aneurysms: A Case-Control Study. In Journal of neurological surgery. Part A, Central European neurosurgery, 85, 142-146. doi:10.1055/s-0043-1761944. https://pubmed.ncbi.nlm.nih.gov/36828013/
6. Crusius, Cassiano Ughini, Cambruzzi, Eduardo, Crusius, Marcelo Ughini, Crusius, Paulo Sérgio, Stefani, Marco Antônio. 2023. CD68 in Cerebral Aneurysms of Smokers and Nonsmokers: An Immunohistochemical Analysis. In Journal of neurological surgery. Part A, Central European neurosurgery, 85, 555-560. doi:10.1055/a-2155-2166. https://pubmed.ncbi.nlm.nih.gov/37586409/
7. Liu, Xu, Zhang, Zengfu, Yuan, Jupeng, Yu, Jinming, Chen, Dawei. 2024. Spatial interaction and functional status of CD68+SHP2+ macrophages in tumor microenvironment correlate with overall survival of NSCLC. In Frontiers in immunology, 15, 1396719. doi:10.3389/fimmu.2024.1396719. https://pubmed.ncbi.nlm.nih.gov/38799432/
8. Jin, Danwen, Qian, Liyong, Chen, Jiayao, Yu, Ze, Dong, Jinliang. . Prognostic impact of CD68+ tumor-associated macrophages in hepatocellular carcinoma: A meta-analysis. In Medicine, 103, e37834. doi:10.1097/MD.0000000000037834. https://pubmed.ncbi.nlm.nih.gov/38640338/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
